Cargando…
A Diagnostic Solution for Lupus Anticoagulant Testing in Patients Taking Direct Oral FXa Inhibitors Using DOAC Filter
Background: Direct oral factor Xa (FXa) inhibitors interfere with lupus anticoagulant (LA) assays challenging antiphospholipid syndrome diagnosis in treated patients. We evaluated a new device, called DOAC Filter, and its usefulness in this setting. It is a single-use filtration cartridge in which F...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8200390/ https://www.ncbi.nlm.nih.gov/pubmed/34136510 http://dx.doi.org/10.3389/fmed.2021.683357 |
_version_ | 1783707591289864192 |
---|---|
author | Farkh, Carine Ellouze, Syrine Gounelle, Louis Sad Houari, Mama Duchemin, Jérôme Proulle, Valérie Fontenay, Michaela Delavenne, Xavier Jourdi, Georges |
author_facet | Farkh, Carine Ellouze, Syrine Gounelle, Louis Sad Houari, Mama Duchemin, Jérôme Proulle, Valérie Fontenay, Michaela Delavenne, Xavier Jourdi, Georges |
author_sort | Farkh, Carine |
collection | PubMed |
description | Background: Direct oral factor Xa (FXa) inhibitors interfere with lupus anticoagulant (LA) assays challenging antiphospholipid syndrome diagnosis in treated patients. We evaluated a new device, called DOAC Filter, and its usefulness in this setting. It is a single-use filtration cartridge in which FXa inhibitor compounds are trapped by non-covalent binding while plasma is filtered through a solid phase. Patient samples were analyzed before and after filtration: 38 rivaroxaban, 41 apixaban, and 68 none. Anticoagulant plasma concentrations were measured using specific anti-Xa assays and HPLC-MS/MS. LA testing was performed using dilute Russell Viper Venom Time (dRVVT) and Silica Clotting Time (SCT). Baseline median [min–max] concentrations were 64.8 [17.6; 311.4] for rivaroxaban and 92.1 ng/mL [37.1; 390.7] for apixaban (HPLC-MS/MS). They were significantly correlated with anti-Xa assay results (r = 0.98 and r = 0.94, respectively). dRVVT was positive in 92% rivaroxaban and 72% apixaban and SCT in 28 and 41% of samples, respectively. Post-filtration, median % of neutralization was 100% with rivaroxaban and apixaban concentrations of, respectively, <2 [<2–2.4] and <2 ng/mL [<2–9.6] using HPLC-MS/MS. No significant effect of DOAC Filter was observed on LA testing in controls (n = 31) and LA-positive (n = 37) non-anticoagulated samples. dRVVT and SCT remained positive in, respectively, 16 and 8% of rivaroxaban and 41 and 18% of apixaban samples. DOAC Filter would be an easy-to-use device allowing FXa inhibitor removal from plasma samples, limiting their interference with LA testing in treated patients. |
format | Online Article Text |
id | pubmed-8200390 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-82003902021-06-15 A Diagnostic Solution for Lupus Anticoagulant Testing in Patients Taking Direct Oral FXa Inhibitors Using DOAC Filter Farkh, Carine Ellouze, Syrine Gounelle, Louis Sad Houari, Mama Duchemin, Jérôme Proulle, Valérie Fontenay, Michaela Delavenne, Xavier Jourdi, Georges Front Med (Lausanne) Medicine Background: Direct oral factor Xa (FXa) inhibitors interfere with lupus anticoagulant (LA) assays challenging antiphospholipid syndrome diagnosis in treated patients. We evaluated a new device, called DOAC Filter, and its usefulness in this setting. It is a single-use filtration cartridge in which FXa inhibitor compounds are trapped by non-covalent binding while plasma is filtered through a solid phase. Patient samples were analyzed before and after filtration: 38 rivaroxaban, 41 apixaban, and 68 none. Anticoagulant plasma concentrations were measured using specific anti-Xa assays and HPLC-MS/MS. LA testing was performed using dilute Russell Viper Venom Time (dRVVT) and Silica Clotting Time (SCT). Baseline median [min–max] concentrations were 64.8 [17.6; 311.4] for rivaroxaban and 92.1 ng/mL [37.1; 390.7] for apixaban (HPLC-MS/MS). They were significantly correlated with anti-Xa assay results (r = 0.98 and r = 0.94, respectively). dRVVT was positive in 92% rivaroxaban and 72% apixaban and SCT in 28 and 41% of samples, respectively. Post-filtration, median % of neutralization was 100% with rivaroxaban and apixaban concentrations of, respectively, <2 [<2–2.4] and <2 ng/mL [<2–9.6] using HPLC-MS/MS. No significant effect of DOAC Filter was observed on LA testing in controls (n = 31) and LA-positive (n = 37) non-anticoagulated samples. dRVVT and SCT remained positive in, respectively, 16 and 8% of rivaroxaban and 41 and 18% of apixaban samples. DOAC Filter would be an easy-to-use device allowing FXa inhibitor removal from plasma samples, limiting their interference with LA testing in treated patients. Frontiers Media S.A. 2021-05-31 /pmc/articles/PMC8200390/ /pubmed/34136510 http://dx.doi.org/10.3389/fmed.2021.683357 Text en Copyright © 2021 Farkh, Ellouze, Gounelle, Sad Houari, Duchemin, Proulle, Fontenay, Delavenne and Jourdi. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Medicine Farkh, Carine Ellouze, Syrine Gounelle, Louis Sad Houari, Mama Duchemin, Jérôme Proulle, Valérie Fontenay, Michaela Delavenne, Xavier Jourdi, Georges A Diagnostic Solution for Lupus Anticoagulant Testing in Patients Taking Direct Oral FXa Inhibitors Using DOAC Filter |
title | A Diagnostic Solution for Lupus Anticoagulant Testing in Patients Taking Direct Oral FXa Inhibitors Using DOAC Filter |
title_full | A Diagnostic Solution for Lupus Anticoagulant Testing in Patients Taking Direct Oral FXa Inhibitors Using DOAC Filter |
title_fullStr | A Diagnostic Solution for Lupus Anticoagulant Testing in Patients Taking Direct Oral FXa Inhibitors Using DOAC Filter |
title_full_unstemmed | A Diagnostic Solution for Lupus Anticoagulant Testing in Patients Taking Direct Oral FXa Inhibitors Using DOAC Filter |
title_short | A Diagnostic Solution for Lupus Anticoagulant Testing in Patients Taking Direct Oral FXa Inhibitors Using DOAC Filter |
title_sort | diagnostic solution for lupus anticoagulant testing in patients taking direct oral fxa inhibitors using doac filter |
topic | Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8200390/ https://www.ncbi.nlm.nih.gov/pubmed/34136510 http://dx.doi.org/10.3389/fmed.2021.683357 |
work_keys_str_mv | AT farkhcarine adiagnosticsolutionforlupusanticoagulanttestinginpatientstakingdirectoralfxainhibitorsusingdoacfilter AT ellouzesyrine adiagnosticsolutionforlupusanticoagulanttestinginpatientstakingdirectoralfxainhibitorsusingdoacfilter AT gounellelouis adiagnosticsolutionforlupusanticoagulanttestinginpatientstakingdirectoralfxainhibitorsusingdoacfilter AT sadhouarimama adiagnosticsolutionforlupusanticoagulanttestinginpatientstakingdirectoralfxainhibitorsusingdoacfilter AT ducheminjerome adiagnosticsolutionforlupusanticoagulanttestinginpatientstakingdirectoralfxainhibitorsusingdoacfilter AT proullevalerie adiagnosticsolutionforlupusanticoagulanttestinginpatientstakingdirectoralfxainhibitorsusingdoacfilter AT fontenaymichaela adiagnosticsolutionforlupusanticoagulanttestinginpatientstakingdirectoralfxainhibitorsusingdoacfilter AT delavennexavier adiagnosticsolutionforlupusanticoagulanttestinginpatientstakingdirectoralfxainhibitorsusingdoacfilter AT jourdigeorges adiagnosticsolutionforlupusanticoagulanttestinginpatientstakingdirectoralfxainhibitorsusingdoacfilter AT farkhcarine diagnosticsolutionforlupusanticoagulanttestinginpatientstakingdirectoralfxainhibitorsusingdoacfilter AT ellouzesyrine diagnosticsolutionforlupusanticoagulanttestinginpatientstakingdirectoralfxainhibitorsusingdoacfilter AT gounellelouis diagnosticsolutionforlupusanticoagulanttestinginpatientstakingdirectoralfxainhibitorsusingdoacfilter AT sadhouarimama diagnosticsolutionforlupusanticoagulanttestinginpatientstakingdirectoralfxainhibitorsusingdoacfilter AT ducheminjerome diagnosticsolutionforlupusanticoagulanttestinginpatientstakingdirectoralfxainhibitorsusingdoacfilter AT proullevalerie diagnosticsolutionforlupusanticoagulanttestinginpatientstakingdirectoralfxainhibitorsusingdoacfilter AT fontenaymichaela diagnosticsolutionforlupusanticoagulanttestinginpatientstakingdirectoralfxainhibitorsusingdoacfilter AT delavennexavier diagnosticsolutionforlupusanticoagulanttestinginpatientstakingdirectoralfxainhibitorsusingdoacfilter AT jourdigeorges diagnosticsolutionforlupusanticoagulanttestinginpatientstakingdirectoralfxainhibitorsusingdoacfilter |